RxDoctor Payments Data

Malgorzata Tiger

Family · Sylva, NCNPI 1497493944

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 92 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$384
  • Gilead$295
  • Otsuka America Pharmaceutical, Inc.$194
  • Lilly USA, LLC$181
  • Indivior Inc.$142
  • Novo Nordisk$84
  • plus $476 from 11 others

What the payments were for

  • Food & beverage$1,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,756 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$9,234
Medicare patients
93
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$42,288
MounjaroTirzepatide20$20,713
SuboxoneBuprenorphine Hcl/Naloxone Hcl23$13,463
Spiriva RespimatTiotropium Bromide20$12,738
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$11,559
Combivent RespimatIpratropium/Albuterol Sulfate20$10,820
EliquisApixaban17$9,909
LinzessLinaclotide13$7,081
JardianceEmpagliflozin11$6,246
Atrovent HfaIpratropium Bromide12$6,024
Buprenorphine25$5,291
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen177$4,355
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen127$3,913
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,853
Gabapentin96$1,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$42,28838 claims
Lilly USA, LLCMounjaro$181$20,71320 claims
Indivior Inc.Suboxone$142$13,46323 claims
PfizerEliquis$15$9,90917 claims
AbbVieLinzess, Armour Thyroid$384$7,92029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Sylva

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →